# Valsamo Anagnostou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/valsamo-anagnostou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,808 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 55 |
| i10-index | 104 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5056510071 |
| ORCID iD | https://orcid.org/0000-0001-9480-3047 |
| Works | 604 |

## Researcher papers

- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Genome-wide cell-free DNA fragmentation in patients with cancer](https://scholariq.org/papers/genome-wide-cell-free-dna-fragmentation-in-patients-with-cancer/)
- [Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer](https://scholariq.org/papers/evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Detection and characterization of lung cancer using cell-free DNA fragmentomes](https://scholariq.org/papers/detection-and-characterization-of-lung-cancer-using-cell-free-dna-fragmentomes/)
- [Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels](https://scholariq.org/papers/association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with/)
- [Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer](https://scholariq.org/papers/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.